IIID Member Company Leads in Advanced Allograft Production

Faravardeh Bafte Iranian, a member company of the Iran International Innovation District, has emerged as a leading firm in regenerative medicine and human tissue processing, leveraging cutting-edge global technology. Aiming to utilize human tissue donations for therapeutic purposes, the company has produced over one million human tissue products to date, aiding in the treatment of patients.

The knowledge-based company, Faravardeh Bafte Iranian, a member of the Iran International Innovation District (IIID), successfully produces human allografts—tissues transplanted from one person to another. The company’s operations are divided into tissue procurement and tissue processing.

According to CEO Amirhossein Tavakoli, the company’s products include tissues such as bone, cartilage, skin, heart valves, and cornea. After processing under completely sterile conditions, these tissues can be transplanted without requiring immunosuppressant drugs, thereby eliminating concerns about graft rejection.

“This technology, which began with knowledge transfer from Europe, has now reached a stage where our country is not only self-sufficient but also ranks among the leading nations in the region,” Tavakoli stated. As an active member of the IIID, Faravardeh Bafte Iranian has localized all stages of tissue processing by expanding its production facilities and utilizing an advanced R&D unit. The company is currently developing new production lines and enhancing product quality.

The products, developed with the help of domestic experts and scientific advisors and approved by Iran’s Food and Drug Administration, are used in a wide range of therapeutic applications, including orthopedics, spine surgery, dentistry, and reconstructive procedures. For example, the bone powder produced by the company offers an effective solution for jaw grafts, reconstruction of damaged bones, and treatment of bone tumors.

Highlighting the importance of the organ and tissue donation culture, Tavakoli mentioned the significant impact of donor families whose decisions save multiple lives. Looking ahead, he noted that the company, recognized as one of the few regional producers of advanced human tissue transplant technologies, plans to expand exports and foster scientific and technological collaborations with foreign companies and universities.

Tavakoli concluded by stating that Iran is at the forefront of global knowledge in tissue engineering and expressed hope that removing legal barriers in fields like cell therapy will further smooth the path for developing advanced therapeutic technologies in the country.

For more information, please visit: https://allograft.co